Entera Bio (NASDAQ:ENTX – Get Rating) posted its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05, Fidelity Earnings reports. Entera Bio had a negative net margin of 2,134.33% and a negative return on equity of 59.83%. During the same period last year, the company earned ($0.43) EPS.
Shares of NASDAQ ENTX traded up $0.06 during midday trading on Friday, hitting $2.15. The company’s stock had a trading volume of 68,010 shares, compared to its average volume of 81,024. The stock has a fifty day moving average price of $2.50 and a 200 day moving average price of $2.80. Entera Bio has a one year low of $1.72 and a one year high of $8.68. The firm has a market capitalization of $50.96 million, a price-to-earnings ratio of -4.67 and a beta of 1.64.
Separately, B. Riley lowered their price target on shares of Entera Bio from $11.00 to $6.00 in a research report on Monday, January 24th.
Entera Bio Company Profile (Get Rating)
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.
- Get a free copy of the StockNews.com research report on Entera Bio (ENTX)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.